Research lane · consciousness and altered states
Can an altered state change symptoms, function, physiological response dynamics, or disease activity, for whom, and at what cost?
ThetaHealing, psychedelics, ayahuasca, ibogaine, ketamine, lucid dreaming, and contemplative absorption are not treated as one mechanism. Vivid experience and ontological interpretation do not establish clinical efficacy.
First scientific task
An intense or meaningful experience can matter while its proposed mechanism remains uncertain. Every source and study in this lane should keep seven layers distinct.
What was experienced, how intensely, and how it changed over time.
Substance, dose, attention, breath, imagery, ritual, music, movement, relationship, preparation, and integration.
Pharmacology, learning, memory updating, attentional control, autonomic regulation, social regulation, sleep, or another specified process.
Symptoms, function, physiology, disease activity, medication use, health-care use, and quality of life measured separately.
Whether change persists, generalizes, relapses, or requires continuing practice.
Acute and delayed medical, psychiatric, relational, financial, and opportunity costs.
Natural history, expectancy, demand, concurrent treatment, selection, reporting bias, support, exposure, or rehabilitation.
Current boundary
These modalities differ in practice, pharmacology, setting, claim, risk, and evidence. Adjacent findings can generate questions. They cannot be used as interchangeable validation.
Official claims established · efficacy speculative
The organization describes prayer, belief work, a theta state, a Creator, DNA activation, and physical and emotional healing. Its current scope page calls the service spiritual and educational, not medical treatment. Neither statement establishes clinical efficacy or a unique theta mechanism.
Plausible signal · highly preliminary
Reviews identify possible benefit, but the literature is small and dominated by low-quality, uncontrolled, survey, and case-based evidence. A five-person psilocybin fibromyalgia pilot supports feasibility questions, not efficacy.
Short-term analgesia plausible · durability unclear
Small chronic-pain and fibromyalgia studies suggest short-term pain reduction. They do not show durable resetting, disease modification, or that the altered experience caused the analgesic effect.
Distinct pharmacologies · material safety boundaries
A small controlled ayahuasca trial in treatment-resistant depression cannot be transferred to chronic illness. Ayahuasca raises interaction questions. Ibogaine has a documented cardiac safety signal, including QT prolongation and serious events.
Measurable experiences · chronic-illness effects speculative
Lucid-dream induction and contemplative absorption can be studied as structured experiences. Existing work does not establish effects on chronic pain, inflammation, disease activity, or durable illness-state change.
Discriminating questions
Preserve some intervention components while changing others. Test whether the state is necessary, sufficient, or incidental to later benefit.
Measure threshold, response size, recovery, recurrence, functional cost, and behavior after the acute experience. Awe, insight, calm, or analgesia alone does not show durable reparameterization.
Keep experience, behavior, symptoms, function, physiology, disease activity, treatment burden, and durability separate.
Test prospective moderators without turning nonresponse into a story about resistance, unreadiness, or personal failure.
Record reports of energy, entities, unity, revelation, past lives, or divine agency as phenomenological and interpretive data, not automatic confirmation of the cosmology described.
Safety and ethics
No informal drug studies. Substance research requires lawful medical and regulatory oversight, substance-specific screening, interaction review, and prospective adverse-event capture. Practice studies also need psychiatric and intensity screening, chronic-illness accommodations, clear exit rights, and consent that does not promise a reset.
High-information next steps
Map modality by condition and separate acute experience, symptoms, function, physiology, disease activity, durability, harms, and null findings.
Interview people who already underwent lawful treatment or practice. Reconstruct baseline, components, concurrent care, behavior change, benefits, harms, relapse, and follow-up without estimating efficacy.
Within a lawful setting, preregister rivals and measure whether later response curves change across experience, behavior, symptoms, function, wearables, and appropriate biomarkers.